Sinolink Securities Co.Ltd(600109)
About Hangzhou Baicheng Pharmaceutical Technology Co., Ltd
Verification opinions on the deposit and use of raised funds in 2021
On November 9, 2021, the China Securities Regulatory Commission approved and issued the reply on Approving the registration of initial public offering of shares of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. (CSRC license [2021] No. 3566), and approved the registration application of initial public offering of shares of the company Sinolink Securities Co.Ltd(600109) (hereinafter referred to as ” Sinolink Securities Co.Ltd(600109) ” or “sponsor”) as the sponsor of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Baicheng pharmaceutical” or “the company”) for initial public offering of shares and listing on the gem, checked the deposit and use of the company’s raised funds in 2021. The details are as follows: 1 Basic information of raised funds (I) actual amount of raised funds and arrival time of funds
Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. publicly issued 27041667 ordinary shares (A shares) to the public at an issue price of 79.60 yuan per share through the reply on Approving the registration of initial public offering of shares of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. (zjxk [2021] No. 3566) issued by China Securities Regulatory Commission, The total raised capital is 215251669320 yuan, and the raised capital after deducting the underwriting and recommendation expenses of 26187750398 yuan is 189063918922 yuan, which has been remitted to the raised capital supervision account of the company by the lead underwriter Sinolink Securities Co.Ltd(600109) on December 15, 2021. In addition, after deducting 2720910081 yuan of additional external expenses directly related to the issuance of equity securities, such as online issuance fee, prospectus printing fee, reporting accountant fee, lawyer fee and evaluation fee, the net amount of funds raised by the company this time is 18634 Dnake (Xiamen) Intelligent Technology Co.Ltd(300884) 1 yuan. The availability of the above raised funds has been verified by Tianjian Certified Public Accountants (special general partnership), who issued the capital verification report (Tianjian Yan [2021] No. 738). (II) use and balance of raised funds
Monetary unit: RMB
Item No. amount
Item No. amount
Net amount of raised funds a 18634 Dnake (Xiamen) Intelligent Technology Co.Ltd(300884) 1
Accumulated amount of project investment as of the beginning of the period B1
Net interest income B2
Project input C1
Net interest income incurred in the current period
C2 67985114
Accumulated amount by the end of the period project input D1 = B1 + C1
Net interest income D2 = B2 + C267985114
The balance of funds raised should be e = a-d1 + D2186410993955
Actual balance of raised funds f 188831904036
Difference [note] g = E-F -2420910081
[note] the difference is 2420910081 yuan of external expenses directly related to the issuance of equity securities, such as online issuance fee, prospectus printing fee, reporting accountant fee, lawyer fee, evaluation fee and so on. 2、 Deposit and management of raised funds (I) management of raised funds
In order to standardize the management and use of raised funds, improve the efficiency and efficiency of fund use, and protect the rights and interests of investors, The company complies with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the Listing Rules of GEM stocks of Shenzhen Stock Exchange (revised in December 2020) (SZS [2020] No. 1292) and the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM (SZS [2022] No. 14) In accordance with the provisions of relevant laws, regulations and normative documents, and in combination with the actual situation of the company, the measures for the administration of the raised funds of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the “measures”). According to the management measures, the company has implemented a special account for the raised funds, set up a special account for the raised funds in the bank, and signed the tripartite supervision agreement for the raised funds with Bank Of Hangzhou Co.Ltd(600926) science and technology sub branch, China Zheshang Bank Co.Ltd(601916) Binjiang sub branch, Hangzhou Branch of Tailong commercial bank, China Merchants Bank Co.Ltd(600036) Qiantang branch, Agricultural Bank Of China Limited(601288) Binjiang sub branch together with the sponsor Sinolink Securities Co.Ltd(600109) , It defines the rights and obligations of all parties. There is no significant difference between the tripartite regulatory agreement and the model tripartite regulatory agreement of Shenzhen Stock Exchange, and the company has strictly complied with the raised funds. (II) storage of raised funds in special account
As of December 31, 2021, the company has five special accounts for raised funds, and the deposits of raised funds are as follows:
Monetary unit: RMB
Remarks on the balance of raised funds in the account number of the deposit bank
Bank Of Hangzhou Co.Ltd(600926) science and technology sub branch 3 Zhangjiagang Zhonghuan Hailu High-End Equipmentco.Ltd(301040) 1 Jinzhou Port Co.Ltd(600190) 2386365054770804 current deposit
China Zheshang Bank Co.Ltd(601916) Binjiang sub branch 331001013012010014852180045318083 current deposit
Talon commercial bank Hangzhou branch 33020010201 Fawer Automotive Parts Limited Company(000030) 95818064972651 current deposit
China Merchants Bank Co.Ltd(600036) Qiantang sub branch 57190891801012319666842498 current deposit
Agricultural Bank Of China Limited(601288) Binjiang sub branch 19045101040063508 Shanghai Pudong Development Bank Co.Ltd(600000) 000 current deposit
Total 188831904036 current deposit
3、 Actual use of raised funds in this year (I) comparison table of use of raised funds
1. See Annex 1 of this report for the comparison table of the use of raised funds.
2. There is no use of over raised funds in this period. (II) description of abnormal conditions in the project invested by raised funds
There is no abnormality in the investment project of the company’s raised funds. (III) description of the situation that the benefits of the investment project with raised funds cannot be calculated separately
The company does not have the situation that the benefits of investment projects with raised funds cannot be calculated separately. 4、 Change the use of funds for investment projects with raised funds
The company does not change the investment projects of the raised funds. V. problems in the use and disclosure of the raised funds
1. The information about the use of raised funds disclosed by the company is not disclosed in a timely, untrue, inaccurate or incomplete manner.
2. There are no violations in the deposit, use, management and disclosure of raised funds.
6、 Verification opinions of the recommendation institution
After verification, the sponsor believes that the use and management of the raised funds of Baicheng pharmaceutical in 2021 are in line with the company’s issuance commitment and the provisions of regulations and documents such as Shenzhen Stock Exchange gem stock listing rules, Shenzhen Stock Exchange self regulatory guidelines No. 2 – Guidelines for the standardized operation of GEM listed companies. The company has made special account storage and special use of the raised funds, and there is no case of changing the purpose of the raised funds in a disguised manner and damaging the interests of shareholders, and there is no case of illegal use of the raised funds. The sponsor has no objection to the use of the raised funds in 2021 disclosed by the board of directors of Baicheng pharmaceutical.
Annex 1
Comparison table of use of raised funds
Year 2021
Prepared by: Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. monetary unit: RMB 10000
Total amount of raised funds 18634301 total amount of raised funds invested in this year
Total amount of raised funds with changed purposes during the reporting period
The accumulated total amount of raised funds with changed purposes has been invested in the total amount of raised funds
Cumulative proportion of total raised funds with changed purposes
Whether the committed investment project has been changed and the raised funds have been adjusted. As of the end of the year, whether the project has reached the scheduled end of the period, whether the project feasibility and the investment of over raised funds in the project (including the total committed investment of the Department, the total investment amount, the cumulative investment amount and the investment progress (%) Benefits realized on the available status date (whether the estimated benefits have changed) (1) (2) (3) = (2) / (1) major changes
Committed investment project 1. Hangzhou Baicheng pharmaceutical
Technology Co., Ltd. not applicable no
Headquarters and R & D department 65051786505178
Heart project commitment investment project
Subtotal – 6505178
Investment direction of over raised funds
1. Supplementary working capital -————
Subtotal of investment of over raised funds
Total – 6505178————
The circumstances and reasons for not reaching the planned progress or expected income (by specific project) are not applicable
The description of major changes in the feasibility of the project is not applicable
The net amount of funds actually raised by the company’s initial public offering of shares is 1863430100 yuan. After deducting the amount, purpose and use progress of the above-mentioned raised funds for investment projects, the total amount of over raised funds is 1212912300 yuan. As of December 31, 2021, the unused over raised funds have been deposited in the special account for raised funds, and the specific purpose shall be determined according to the subsequent development needs of the company and relevant regulations.
The change of the implementation location of the project invested by raised funds is not applicable
raise
